Skip to main content

Table 2 Comparisons of whole CBF outcomes in ipsilateral MCA territory of carotid artery system stenosis between NBP and placebo groups

From: DL-3-n-butylphthalide improves cerebral hypoperfusion in patients with large cerebral atherosclerotic stenosis: a single-center, randomized, double-blind, placebo-controlled study

Number of ROIs with rCBF amelioration/deterioration

Group

Deterioration

n (%)

Stablization

n (%)

Amelioration

n (%)

χ2

P values

≥1

NBP

10 (20.8%)

23 (47.9%)

15 (31.2%)

2.049

0.359

Control

15 (32.6%)

21 (45.7%)

10 (21.7%)

≥2

NBP

1 (2.1%)

37 (77.1%)

10 (20.8%)

11.362

0.003

Control

12 (26.1%)

27 (58.7%)

7 (15.2%)

≥3

NBP

1 (2.1%)

40 (83.3%)

7 (14.6%)

8.799

0.012

Control

10 (21.7%)

31 (67.4%)

5 (10.9%)

≥4

NBP

0 (0.0%)

43 (89.6%)

5 (10.4%)

6.441

0.015

Control

5 (10.9%)

39 (84.8%)

2 (4.3%)

  1. Definitions of whole CBF outcomes were according to the number of ROIs with rCBF amelioration/deterioration. CBF cerebral blood flow, MCA middle cerebral artery, NBP Dl-3-butylphthalide, ROI regions of interest, rCBF regional CBF
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us